Stimulant Use in Brain Tumor Patients

Primary Indications for Stimulant Use

Methylphenidate can be considered for cancer-related fatigue in brain tumor patients, though evidence shows mixed results 1, 2.
A meta-analysis found methylphenidate effective in reducing fatigue compared to placebo, but effect sizes were small and one study showed no superiority over placebo 1.
Critically, d-threo-methylphenidate did NOT show efficacy in preventing fatigue during radiotherapy specifically for brain tumors 1, 2.
Side effects of methylphenidate include headache, nausea, insomnia, agitation, anorexia, and dry mouth, though these are generally reported as minor 1, 3.

For cognitive impairment, stimulants are reasonable as a last-line therapy after nonpharmacologic interventions have been insufficient 4, 5, 6.
Modafinil shows more consistent positive results than methylphenidate for cognitive function in brain tumor patients 4, 5, 6.
Modafinil improved memory, attention, and psychomotor speed in cancer survivors, with benefits also noted in primary brain tumor patients 4, 5, 6.

Modafinil appears to be the preferred stimulant choice for brain tumor patients based on more consistent positive outcomes 1, 2, 4, 5, 6.
Dosing of modafinil typically starts at 100-200 mg daily, with titration up to 600 mg as needed 1, 2.
83% of patients in one open-label study reported improvement in fatigue with modafinil 1, 3.
However, modafinil is NOT FDA-approved for cancer-related fatigue and lacks large randomized controlled trials 1, 2.

Prophylactic antiepileptic drugs (AEDs) should NOT be prescribed to brain tumor patients who have never had a seizure (Level A recommendation) 7.
If the patient has had seizures, levetiracetam is preferred over older AEDs to reduce side effects 7, 8, 9.
Levetiracetam and valproic acid are non-enzyme-inducing options if AEDs are needed 9.

Assess the specific indication: Is this for fatigue, cognitive dysfunction, or both? 5.
Try nonpharmacologic interventions first for cognitive dysfunction (exercise, cognitive rehabilitation) 4, 5, 6.
For fatigue or cognitive impairment refractory to conservative measures, first choice is Modafinil 100-200 mg daily, titrate as needed 1, 2, 4, 5, 6.
Alternative is Methylphenidate 10 mg twice daily, increase to 20-30 mg twice daily if tolerated 4, 5, 6.
Monitor for insomnia, agitation, headache, nausea, anorexia 1, 3.
Do NOT use prophylactic AEDs unless the patient has a seizure history 7.
Reassess efficacy at 2-4 weeks and discontinue if no benefit 1, 2.

The overall evidence quality is very low across all stimulant studies in brain tumor patients 1, 2.
NCCN guidelines state insufficient evidence exists to definitively recommend wakefulness-enhancing drugs for cancer-related fatigue, recommending more research 1, 2.
The 2022 Society for Neuro-Oncology guidelines do not specifically address stimulant use, focusing instead on supportive medications like anti-emetics and analgesics 10.